LG Up Against Samsung After Korea Biosimilar Etanercept Nod
Following its approval in Japan earlier this year, LG Chem's etanercept biosimilar Eucept has gained the green light in South Korea, where it is set to compete directly with Samsung Bioepis's biosimilar this year.
You may also be interested in...
As the year end approaches, Scrip wraps up what major events made headlines in the South Korean pharma/biotech sector in 2018.
Plus deals involving Astellas/Actinium, Sosei/PharmEnable, Aadi/EOC Pharma, BeiGene/Strand, Chi-Med/Inmagene, Alteogen/Intas, Sosei/AbbVie, Y-Biologics/3D Medicines.
After accumulating technologies to develop off-the-shelf, allogeneic NK cell therapies over the past decade, Korea's GC LabCell is now tapping into the global market as US partner Artiva begins clinical trials of its lead asset.